Nifty Pharma index ends 2.72% higher. Top gainers: COMPANY LATEST PREV CLOSE GAIN() GAIN(%) AUROBINDO PHARMA 759.30 696.95 62.35 8.95 BIOCON 662.95 624.05 38.90 6.23 CADILA HEALTH. 422.35 401.95 20.40 5.08 DIVI'S LAB. 1317.00 1278.05 38.95 3.05 CIPLA 662.10 646.55 15.55 2.41 Nifty sectoral gainers and losers of the day BSE Sensex: RIL, Coal India, Sun Pharma among top gainers of the day Market at close The S&P BSE Sensex ended at 38,243, up 224 points while the broader Nifty50 index settled at 11,537, up 60 points. Sun Pharma, Glenmark Pharma, Hikal hit 52-week highs; Aurobindo surges 8% Shares of pharmaceutical companies were back in focus with Sun Pharmaceutical Industries and Glenmark Pharmaceuticals hitting their respective 52-week highs on the National Stock Exchange (NSE). Aurobindo Pharma has rallied 8%, while Biocon, Divi’s Laboratories, Cadila Healthcare and Cipla from the Nifty Pharma index gained in the range of 2.5% to 4% on the NSE. READ MORE Wipro gains for seventh straight trading day; stock up 16% in one month Shares of Wipro were up for the seventh straight day, rising to Rs 322, up 1% on the BSE. In past three trading days, the stock has risen 4% after the information technology (IT) services firm on Sunday announced that it has won its largest contract to date from US-based human resources (HR) and financial solutions company Alight Solutions LLC. The stock hit a high of Rs 328 during intra-day trade on Monday, September 3, 2018. READ MORE
The S&P BSE Sensex ended at 38,243, up 224 points while the broader Nifty50 index settled at 11,537, up 60 points.
Among sectoral indices, Nifty Pharma index settled 2.7 per cent higher led by Aurobindo Pharma and Biocon.
In individual stocks Reliance Industries (RIL) rose 2.7 per cent higher to end the day at Rs 1,259 on the BSE.
Rupee hits 72/$
Asian shares skidded for a sixth straight session on Thursday, oil slipped and safe-haven gold gained with investor confidence shaken by turmoil in emerging markets and jitters over a potentially severe escalation in the US-China trade war.
(with Reuters inputs)